Global Prostate Cancer Therapeutics Market Overview
Prostate Cancer remains a top priority for health systems around the world as incidence level rises, fueled by growing and aging populations. The main drivers for the prostate cancer market are the increase in the global aging population, innovation in drugs and developments in genomics and proteomics. The prostate cancer market faces some hindrances as well such as the high cost of prostate cancer drugs, low success rate of clinical trials and side effects of treatments among others.
Global Prostate Cancer - Key Therapies Analysis: The global market for prostate cancer therapeutics is increasing, driven primarily by the growth in the hormonal therapy markets. Chemotherapy was the second leading therapy for prostate cancer in 2014. However, growth in the targeted therapy is predicted to push chemotherapy back at the third position, while immunotherapy for prostate cancer stands at the last positon in the prostate cancer therapeutics market.
Prostate Cancer Drugs Analysis: Zytiga leads the prostate cancer drugs market in 2014. Zytiga is facing stiff competition from Xtandi drugs which is expected to replace Zytiga as the leading prostate cancer drugs. In prostate cancer drugs market, Leuplin and Zoladex stand at the third and fourth position in 2014. The market share of both Leuplin and Zoladex is likely to plunge during the forecasting period. Lupron is standing at the fifth position. Bayer’s targeted therapy drugs Xofigo is also rapidly catching up the market due to advantages such as increase in the overall survival and progression free survival with benign side effects profile.
iGATE RESEARCH report titled “Global Prostate Cancer Therapeutics Market to 2020” is a 76 page report with 43 Figures and 4 Tables. This report analyses the Prostate Cancer Therapy Market, Prostate Cancer Drugs Market, driving factors and challenges for prostate cancer market.
The 4 Prostate Cancer Therapy Market covered in the report are as follows:
1. Hormonal Therapy
4. Targeted Therapy
The above 4 Therapy has been further analyzed in terms of drugs sales and forecast (2011 - 2020):
1. Global Prostate Cancer - Hormonal Therapy Drugs Market
- Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists - Zytiga, Gonax
- Luteinizing Hormone-Releasing Hormone (LHRH) Analogs - Lupron, Zoladex, Decapeptyl, Eligard, Vantas, Leuplin
- Anti-Androgens - Casodex, Xtandi or MDV3100, Xtandi US or MDV3100
2. Global Prostate Cancer - Chemotherapy Drugs Market
3. Global Prostate Cancer - Immunotherapy Drugs Market
4. Global Prostate Cancer - Targeted Therapy Drugs Market
1. Xofigo or Alpharadin
Source of Information
iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.
Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.
Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.